CTX310 Lipid Disorder: Phase 1 Trial Shows Prom...

By HEOR Staff Writer

November 10, 2025

CTX310 Breakthrough in Lipid Disorder Treatment CTX310 is a significant advancement as the first-in-human Phase 1 trial of this
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Accelerated UK Clinical Trial Reforms: Enhancing Approvals with AI and Effici...
Antidepressant Side Effects: New Insights on Cardiometabolic Health Risks
AI Chatbot Delusions: Navigating the Risks of Validation in Mental Health
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fa...
Navigating Novo Nordisk Board Changes: Leadership for Growth and Strategy
Keytruda Lung Cancer Treatment: Long-Term Survival Gains in NSCLC
Cabotegravir HIV Prevention: First Injectable PrEP Recommended for High-Risk ...
Social Media Policy Action: Protecting Youth from Cognitive Risks
Johnson & Johnson Advances Solid Tumor Research at ESMO 2025 with Promis...